Search for Clinical Trial Results
Mucopolysaccharidosis Type I - 128 Studies Found
Status | Study |
Not yet recruiting |
Study Name: Study of Idursulfase-beta (GC1111) in Hunter Syndrome Condition: Mucopolysaccharidosis II Date: 2016-01-17 Interventions:
|
Enrolling by invitation |
Study Name: Long-Term Safety and Clinical Outcomes of Idursulfase IT and Elaprase Treatment in Pediatric Patients With Hunter Syndrome That Have Completed Study HGT-HIT-094 Condition: Hunter Syndrome Date: 2015-04-01 Interventions: Drug: Idursulfase-IT Patients will receive idursulfase-IT treatment once every 28 days at a dose of 10 m |
Completed |
Study Name: Screening Study to Identify Pediatric Patients With Hunter Syndrome Who Demonstrate Evidence of Central Nervous System (CNS) Involvement and Who Are Currently Receiving Treatment With Elaprase® Condition: Hunter Syndrome Date: 2009-07-09 Interventions:
|
Recruiting |
Study Name: Ascending Dose Study of Genome Editing by the Zinc Finger Nuclease (ZFN) Therapeutic SB-913 in Subjects With MPS II Condition: Mucopolysaccharidosis II Date: 2017-01-13 Interventions: Biological: SB-913 Single dose of each of the 3 components of SB-913: ZFN1, ZFN2 and hIDS Donor |
Active, not recruiting |
Study Name: Study of Intrathecal Idursulfase-IT Administered in Conjunction With Elaprase® in Pediatric Patients With Hunter Syndrome and Early Cognitive Impairment Condition: Date: 2024-05-10 |
Active, not recruiting |
Study Name: Extension of HGT-HIT-045 Evaluating Long-Term Safety and Clinical Outcomes of Idursulfase (IT)in Conjunction With Elaprase in Pediatric Patients With Hunter Syndrome and Cognitive Impairment Condition: Hunter Syndrome Date: 2011-12-15 Interventions: Drug: Idursulfase-IT Idursulfase-IT administered once monthly at the dose used in study HGT-HIT-045 via |
Completed |
Study Name: Extension of Study TKT024 Evaluating Long-Term Safety and Clinical Outcomes in MPS II Patients Receiving Idursulfase Condition:
|
Completed |
Study Name: Safety and Clinical Outcomes in Hunter Syndrome Patients 5 Years of Age and Younger Receiving Idursulfase Therapy Condition:
|
Completed |
Study Name: Observational Study to Evaluate Neurodevelopmental Status in Pediatric Patients With Hunter Syndrome (MPS II) Condition:
Date: 2013-03-12 |
Completed |
Study Name: Phase I/II Study of Retroviral-Mediated Transfer of Iduronate-2-Sulfatase Gene Into Lymphocytes of Patients With Mucopolysaccharidosis II (Mild Hunter Syndrome) Condition: Mucopolysaccharidosis II Date: 1999-10-18 Interventions: Genetic: lymphocyte gene therapy |